Phage therapy against Achromobacter xylosoxidans lung infection in a patient with cystic fibrosis: a case report

Research in Microbiology

Volumn 169, Issue 9, 2018, Pages 540-542

  Hoyle, N ^a   Zhvaniya, P ^a   Balarjishvili, N ^b   Bolkvadze, D ^b   Nadareishvili, L ^a   Nizharadze, D ^a   Wittmann, J ^c   Rohde, C ^c   Kutateladze, M ^b  

^a Eliava Biopreparation Phage Therapy Center   (Georgia)

^b George Eliava Institute for Bacteriology   (Georgia)

^c LEIBNIZ INSTITUTE DSMZ GERMAN COLLECTION OF MICROORGANISMS AND CELL CULTURES   (Germany)

Author keywords

Achromobacter xylosoxidans; Antibiotic resistance; Bacteriophage; Cystic fibrosis; Phage therapy; Respiratory infection

Indexed keywords

ANTIBIOTIC AGENT; CIPROFLOXACIN; COLISTIN; COTRIMOXAZOLE; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; PIPERACILLIN; SALBUTAMOL; SODIUM CHLORIDE; TOBRAMYCIN; ANTIINFECTIVE AGENT;

ACHROMOBACTER XYLOSOXIDANS; ADOLESCENT; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL PNEUMONIA; BURKHOLDERIA CEPACIA INFECTION; CASE REPORT; CHEST WALL OSCILLATION; CLINICAL ARTICLE; CLINICAL EXAMINATION; COUGHING; CRACKLE; CYSTIC FIBROSIS; DYSPNEA; FEMALE; GENE MUTATION; GRAM NEGATIVE INFECTION; HIGH FREQUENCY OSCILLATION; HOMOZYGOSITY; HOSPITALIZATION; HUMAN; MECONIUM ILEUS; MULTIDRUG RESISTANCE; OXYGEN SATURATION; PHAGE THERAPY; PHYSIOTHERAPY; PRIORITY JOURNAL; PSEUDOMONAS INFECTION; RESPIRATORY TRACT INFECTION; SPUTUM CULTURE; STAPHYLOCOCCUS INFECTION; ACHROMOBACTER DENITRIFICANS; ANTIBIOTIC RESISTANCE; COMPLICATION; DRUG EFFECT; LUNG; MICROBIOLOGY;

ACHROMOBACTER DENITRIFICANS; ADOLESCENT; ANTI-BACTERIAL AGENTS; CYSTIC FIBROSIS; DRUG RESISTANCE, BACTERIAL; FEMALE; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; LUNG; PHAGE THERAPY; PNEUMONIA, BACTERIAL;

EID: 85048135675     PISSN: 09232508     EISSN: 17697123     Source Type: Journal    
DOI: 10.1016/j.resmic.2018.05.001     Document Type: Article

References (43)

1. Riordan, J.R., Rommens, J.M., Kerem, B., Alon, N., Rozmahel, R., Grzelczak, Z., et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science (New York, NY) 245 (1989), 1066–1073.
2. Dodge, J.A., Lewis, P.A., Stanton, M., Wilsher, J., Cystic fibrosis mortality and survival in the UK: 1947–2003. Eur Respir J 29 (2007), 522–526.
3. Szaff, M., Hoiby, N., Flensborg, E.W., Frequent antibiotic therapy improves survival of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection. Acta Paediatr Scand 72 (1983), 651–657.
4. Flume, P.A., Mogayzel, P.J. Jr., Robinson, K.A., Goss, C.H., Rosenblatt, R.L., Kuhn, R.J., et al. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am J Respir Care Med 180 (2009), 802–808.
5. Cox, M.J., Allgaier, M., Taylor, B., Baek, M.S., Huang, Y.J., Daly, R.A., et al. Airway microbiota and pathogen abundance in age-stratified cystic fibrosis patients. PLoS One, 5, 2010, e11044.
6. Fodor, A.A., Klem, E.R., Gilpin, D.F., Elborn, J.S., Boucher, R.C., Tunney, M.M., et al. The adult cystic fibrosis airway microbiota is stable over time and infection type, and highly resilient to antibiotic treatment of exacerbations. PLoS One, 7, 2012, e45001.
7. Guss, A.M., Roeselers, G., Newton, I.L., Young, C.R., Klepac-Ceraj, V., Lory, S., et al. Phylogenetic and metabolic diversity of bacteria associated with cystic fibrosis. ISME J 5 (2011), 20–29.
8. Sriramulu, D., Evolution and impact of bacterial drug resistance in the context of cystic fibrosis disease and nosocomial settings. Microbiol Insights 6 (2013), 29–36.
9. Davis, P.B., Drumm, M., Konstan, M.W., Cystic fibrosis. Am J Respir Crit Care Med 154 (1996), 1229–1256.
10. Kvachadze, L., Balarjishvili, N., Meskhi, T., Tevdoradze, E., Skhirtladze, N., Pataridze, T., et al. Evaluation of lytic activity of staphylococcal bacteriophage Sb-1 against freshly isolated clinical pathogens. Microb Biotechnol 4 (2011), 643–650.
11. Abedon, S.T., Kuhl, S.J., Blasdel, B.G., Kutter, E.M., Phage treatment of human infections. Bacteriophage 1 (2011), 66–85.
12. Debarbieux, L., Leduc, D., Maura, D., Morello, E., Criscuolo, A., Grossi, O., et al. Bacteriophages can treat and prevent Pseudomonas aeruginosa lung infections. J Infect Dis 201 (2010), 1096–1104.
13. Waters, E.M., Neill, D.R., Kaman, B., Sahota, J.S., Clokie, M.R.J., Winstanley, C., et al. Phage therapy is highly effective against chronic lung infections with Pseudomonas aeruginosa. Thorax 72 (2017), 666–667.
14. Yabuuchi, E., Oyama, A., Achromobacter xylosoxidans n. sp. from human ear discharge. Jpn J Microbiol 15 (1971), 477–481.
15. Rodrigues, C.G., Rays, J., Kanegae, M.Y., Native-valve endocarditis caused by Achromobacter xylosoxidans: a case report and review of literature. Autops Case Rep 7 (2017), 50–55.
16. Behrens-Muller, B., Conway, J., Yoder, J., Conover, C.S., Investigation and control of an outbreak of Achromobacter xylosoxidans bacteremia. Infect Control Hosp Epidemiol 33 (2012), 180–184.
17. Park, J.H., Song, N.H., Koh, J.W., Achromobacter xylosoxidans keratitis after contact lens usage. Korean J Ophthalmol 26 (2012), 49–53.
18. Tena, D., Gonzalez-Praetorius, A., Perez-Balsalobre, M., Sancho, O., Bisquert, J., Urinary tract infection due to Achromobacter xylosoxidans: report of 9 cases. Scand J Infect Dis 40 (2008), 84–87.
19. Davies, J.C., Rubin, B.K., Emerging and unusual gram-negative infections in cystic fibrosis. Semin Respir Crit Care Med 28 (2007), 312–321.
20. Edwards, B.D., Greysson-Wong, J., Somayaji, R., Waddell, B., Whelan, F.J., Storey, D.G., et al. Prevalence and outcomes of achromobacter species infections in adults with cystic fibrosis: a North American cohort study. J Clin Microbiol 55 (2017), 2074–2085.
21. Somayaji, R., Stanojevic, S., Tullis, D.E., Stephenson, A.L., Ratjen, F., Waters, V., Clinical outcomes associated with achromobacter species infection in patients with cystic fibrosis. An Am Thora Soc 14 (2017), 1412–1418.
22. Mahenthiralingam, E., Emerging cystic fibrosis pathogens and the microbiome. Paediatr Respir Rev 15:Suppl. 1 (2014), 13–15.
23. Trancassini, M., Iebba, V., Citera, N., Tuccio, V., Magni, A., Varesi, P., et al. Outbreak of Achromobacter xylosoxidans in an Italian cystic fibrosis center: genome variability, biofilm production, antibiotic resistance, and motility in isolated strains. Front Microbiol, 5, 2014, 138.
24. Liu, C., Guo, J., Yan, W., Jin, Y., Pan, F., Fang, X., et al. Hospital-acquired pneumonia due to Achromobacter xylosoxidans in the elderly: a single-center retrospective study in Beijing. J InfectDev Ctries 11 (2017), 10–18.
25. Li, X., Hu, Y., Gong, J., Zhang, L., Wang, G., Comparative genome characterization of Achromobacter members reveals potential genetic determinants facilitating the adaptation to a pathogenic lifestyle. ApplMicrobiol Biotechnol 97 (2013), 6413–6425.
26. Amoureux, L., Bador, J., Fardeheb, S., Mabille, C., Couchot, C., Massip, C., et al. Detection of Achromobacter xylosoxidans in hospital, domestic, and outdoor environmental samples and comparison with human clinical isolates. Appl Environm Microbiol 79 (2013), 7142–7149.
27. Ridderberg, W., Bendstrup, K.E., Olesen, H.V., Jensen-Fangel, S., Norskov-Lauritsen, N., Marked increase in incidence of Achromobacter xylosoxidans infections caused by sporadic acquisition from the environment. J Cyst Fibro 10 (2011), 466–469.
28. Ridderberg, W., Wang, M., Norskov-Lauritsen, N., Multilocus sequence analysis of isolates of Achromobacter from patients with cystic fibrosis reveals infecting species other than Achromobacter xylosoxidans. J Clin Microbiol 50 (2012), 2688–2694.
29. Spilker, T., Vandamme, P., Lipuma, J.J., Identification and distribution of Achromobacter species in cystic fibrosis. J Cystic Fibros 12 (2013), 298–301.
30. Swenson, C.E., Sadikot, R.T., Achromobacter respiratory infections. Ann Am Thorac Soc 12 (2015), 252–258.
31. Wittmann, J., Dreiseikelmann, B., Rohde, C., Rohde, M., Sikorski, J., Isolation and characterization of Numerous Novel phages targeting diverse strains of the ubiquitous and opportunistic pathogen achromobacter xylosoxidans. PLoS One, 9, 2014, e86935.
32. Yamamoto, M., Nagao, M., Hotta, G., Matsumura, Y., Matsushima, A., Ito, Y., et al. Molecular characterization of IMP-type metallo-beta-lactamases among multidrug-resistant Achromobacter xylosoxidans. J Antimicrob Chemother 67 (2012), 2110–2113.
33. Levesque, R., Letarte, R., Pechere, J.C., Comparative study of the beta-lactamase activity found in Achromobacter. Can J Microbiol 29 (1983), 819–826.
34. Bador, J., Amoureux, L., Blanc, E., Neuwirth, C., Innate aminoglycoside resistance of Achromobacter xylosoxidans is due to AxyXY-OprZ, an RND-type multidrug efflux pump. Antimicrob Agents Chemother 57 (2013), 603–605.
35. Dreiseikelmann, B., Bunk, B., Sproer, C., Rohde, M., Nimtz, M., Wittmann, J., Characterization and genome comparisons of three Achromobacter phages of the family Siphoviridae. Arch Virol 162 (2017), 2191–2201.
36. Rolain, J.M., Fancello, L., Desnues, C., Raoult, D., Bacteriophages as vehicles of the resistome in cystic fibrosis. J Antimicrob Chemother 66 (2011), 2444–2447.
37. Winstanley, C., Langille, M.G., Fothergill, J.L., Kukavica-Ibrulj, I., Paradis-Bleau, C., Sanschagrin, F., et al. Newly introduced genomic prophage islands are critical determinants of in vivo competitiveness in the liverpool epidemic strain of Pseudomonas aeruginosa. Genome Res 19 (2009), 12–23.
38. Friman, V.P., Ghoul, M., Molin, S., Johansen, H.K., Buckling, A., Pseudomonas aeruginosa adaptation to lungs of cystic fibrosis patients leads to lowered resistance to phage and protist enemies. PLoS One, 8, 2013, e75380.
39. Hraiech, S., Bregeon, F., Rolain, J.M., Bacteriophage-based therapy in cystic fibrosis-associated Pseudomonas aeruginosa infections: rationale and current status. Drug Des Devel Ther 9 (2015), 3653–3663.
40. Sokurenko, E.V., Gomulkiewicz, R., Dykhuizen, D.E., Source-sink dynamics of virulence evolution. Nat Rev Microbiol 4 (2006), 548–555.
41. Zschach, H., Joensen, K.G., Lindhard, B., Lund, O., Goderdzishvili, M., Chkonia, I., et al. What can we learn from a metagenomic analysis of a Georgian bacteriophage cocktail?. Viruses 7 (2015), 6570–6589.
42. Feigelman, R., Kahlert, C.R., Baty, F., Rassouli, F., Kleiner, R.L., Kohler, P., et al. Sputum DNA sequencing in cystic fibrosis: non-invasive access to the lung microbiome and to pathogen details. Microbiome, 5, 2017, 20.
43. Lambiase, A., Catania, M.R., Del Pezzo, M., Rossano, F., Terlizzi, V., Sepe, A., et al. Achromobacter xylosoxidans respiratory tract infection in cystic fibrosis patients. Eur J Clin Microbiol Infect Dis 30 (2011), 973–980.